GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer
Authors
Stephanie Lustgarten
Robert Louis Coleman (ORCID: https://orcid.org/0000-0001-9343-8754)
Bradley J. Monk (ORCID: https://orcid.org/0000-0001-6985-0159)
David M. Gershenson (ORCID: https://orcid.org/0000-0001-9712-2140)
David M. O’Malley (ORCID: https://orcid.org/0000-0002-2828-0177)
Premal H. Thaker (ORCID: https://orcid.org/0000-0002-0568-6959)
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer
Stephanie Lustgarten, Robert Louis Coleman, Bradley J. Monk, David M. Gershenson et al.
Citations
22 citations
Journal
International Journal of Gynecological Cancer
Topics
Ovarian cancer diagnosis and treatment
Field-Weighted Citation Impact (FWCI)
11.82
article
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer
Stephanie Lustgarten, Robert Louis Coleman, Bradley J. Monk, David M. Gershenson, David M. O’Malley, Premal H. Thaker, Lauren Cobb, Rachel N. Grisham, Carol Aghajanian, Susana Banerjee, Hagop Youssoufian, Ana Oaknin, Kathleen N. Moore, Yeh Chen Lee, Philipp Harter, Mansoor Raza Mirza, Els Van Nieuwenhuysen, Michel Fabbro, Nicoletta Colombo, Chel Hun Choi, Amit M Oza
article en
22 citations
Abstract
No abstract available for this paper.
Publication Tag
International Journal of Gynecological CancerVol. 35(11)
Institutions
Royal Marsden NHS Foundation Trust (GB), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), University of Milan (IT), Washington University in St. Louis (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Samsung Medical Center (KR), Copenhagen University Hospital (DK), Princess Margaret Cancer Centre (CA), Rigshospitalet (DK), UNSW Sydney (AU), Florida Cancer Specialists & Research Institute (US), Institut de Recherche en Cancérologie de Montpellier (FR), Kliniken Essen-Mitte (DE), The US Oncology Network (US), Verastem (United States) (US), Institut Regional du Cancer de Montpellier (FR), Vall d'Hebron Institute of Oncology (ES), European Institute of Oncology (IT), University of Oklahoma (US), KU Leuven (BE)